Imsidolimab ( DrugBank: Imsidolimab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 37 | 膿疱性乾癬（汎発型） | 7 |
37. 膿疱性乾癬（汎発型）
臨床試験数 : 79 / 薬物数 : 57 - (DrugBank : 21) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05366855 (ClinicalTrials.gov) | April 21, 2022 | 25/4/2022 | Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis | Generalized Pustular Psoriasis | Biological: Imsidolimab;Other: Placebo | AnaptysBio, Inc. | NULL | Recruiting | 18 Years | 80 Years | All | 45 | Phase 3 | United States;Australia;France;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Spain;Taiwan;Thailand;Tunisia;Turkey |
| 2 | NCT05352893 (ClinicalTrials.gov) | April 14, 2022 | 25/4/2022 | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis | Generalized Pustular Psoriasis | Drug: Imsidolimab high dose;Drug: Imsidolimab low dose;Other: Placebo | AnaptysBio, Inc. | NULL | Recruiting | 18 Years | 80 Years | All | 45 | Phase 3 | United States;Australia;Georgia;Germany;Korea, Republic of;Malaysia;Morocco;Poland;Romania;Slovakia;Spain;Taiwan;Thailand;Tunisia;Turkey |
| 3 | EUCTR2021-001447-27-ES (EUCTR) | 07/02/2022 | 12/11/2021 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Efficacy and Safety of Imsidolimab in Subjects with Generalized Pustular Psoriasis | Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody | AnaptysBio Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of | ||
| 4 | EUCTR2021-001448-90-FR (EUCTR) | 02/02/2022 | 05/10/2021 | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized Pustular Psoriasis | Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody | AnaptysBio Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | France;Taiwan;Spain;Malaysia;Thailand;Australia;Georgia;Germany;Korea, Republic of | ||
| 5 | EUCTR2021-001448-90-ES (EUCTR) | 21/01/2022 | 19/10/2021 | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized Pustular Psoriasis | Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody | AnaptysBio Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | Taiwan;Thailand;Malaysia;Spain;Australia;Georgia;Germany;Korea, Republic of | ||
| 6 | EUCTR2021-001448-90-DE (EUCTR) | 08/12/2021 | 08/09/2021 | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis | A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized Pustular Psoriasis | Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody | AnaptysBio Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | United States;Taiwan;Spain;Thailand;United Kingdom;France;Malaysia;Poland;Romania;Australia;Georgia;Germany;Korea, Republic of | ||
| 7 | EUCTR2021-001447-27-DE (EUCTR) | 08/12/2021 | 08/09/2021 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis - Efficacy and Safety of Imsidolimab in Subjects with Generalized Pustular Psoriasis | Subjects with generalized pustular psoriasis MedDRA version: 20.0;Level: PT;Classification code 10037575;Term: Pustular psoriasis;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody Product Code: ANB019 INN or Proposed INN: anti-IL-36R monoclonal antibody | AnaptysBio Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | Georgia;Germany;United States;Taiwan;Spain;Thailand;United Kingdom;France;Malaysia;Poland;Romania;Australia;Korea, Republic of |